# AACR Special Conference on Endometrial Cancer: New Biology Driving Research and Treatment

> **NIH NIH R13** · AMERICAN ASSOCIATION FOR CANCER RESEARCH · 2020 · $5,000

## Abstract

PROJECT SUMMARY
The proposed conference, entitled “Endometrial Cancer: New Biology Driving Research
and Treatment,” will be held November 7-9, 2020 in Miami, Florida. This will be the first AACR
conference focused specifically on advances in endometrial cancer (EC). Over the last decade,
the incidence of EC has been increasing globally. If current trends continue, in the United States
the incidence of EC will double by 2030. Furthermore, the number of women dying from EC has
also been increasing disproportionately to the rise in incidence, with rates exceeding those seen
for most other solid tumors. There are few therapeutic options for women diagnosed with
recurrent or metastatic EC, and median overall survival (OS) is short. No new agents have been
approved for the treatment of EC in the past two decades. Emerging molecular knowledge of
EC has led to clinical trials testing actionable events in molecularly defined recurrent EC patient
populations. Molecular subtypes of EC have been well defined by The Cancer Genome Atlas
Program and are now being incorporated into clinical trials and transitioned into clinical practice.
Tangentially, based on these studies, the FDA has approved therapies based on microsatellite
instability and mutational burden. Many emerging therapies are based on molecular
characterization of EC in addition to histologic subtypes. There are also many cooperative group
clinical trials completed, in progress, and approved for EC using novel biologic approaches. This
suggests that numerous opportunities exist for diagnostics, prognostics, and therapeutics that
would benefit from an AACR special conference. To this end, the AACR is seeking support to
expand the conference and to recruit outstanding young investigators through additional travel
awards. Attendance by this “next generation” of cancer scientists and caregivers will help better
disseminate the rapidly growing collection of research innovations as well as ignite powerful
collaborations. The program has been carefully designed to feature thought-provoking sessions
on molecular stratification, DNA repair and replication, functional genomics and proteomics,
novel model systems, immunotherapy, and targeted therapies. Collaboration and networking will
be encouraged by incorporating multiple opportunities for education, thoughtful discussion, and
meaningful interaction between participants.

## Key facts

- **NIH application ID:** 10070914
- **Project number:** 1R13CA254055-01
- **Recipient organization:** AMERICAN ASSOCIATION FOR CANCER RESEARCH
- **Principal Investigator:** Margaret Foti
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $5,000
- **Award type:** 1
- **Project period:** 2020-09-01 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10070914

## Citation

> US National Institutes of Health, RePORTER application 10070914, AACR Special Conference on Endometrial Cancer: New Biology Driving Research and Treatment (1R13CA254055-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10070914. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*